NEW YORK (GenomeWeb) – As Adaptive Biotechnologies expands its business from immune repertoire sequencing into therapeutics, it is developing tools that it can use to identify biomarkers to help in the development of immunotherapies.

The company recently presented some of its work in this area at the American Association of Immunologists meeting in Seattle. In addition, following the meeting, Adaptive CSO Harlan Robins spoke to GenomeWeb about a new assay the company has developed called MIRA, for multiplexed identification of T cell receptor antigen specificity.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.